Shots:
- AbbVie has reported the P-III (ECLIPSE) trial data assessing Aquipta/Qulipta (atogepant, 60mg, PO, QD) vs PBO as an acute treatment of migraine in 1,223 adults (with or without aura)
- Trial met its 1EP, showing atogepant was superior to PBO for pain freedom at 2hrs. in the first treated migraine attack (with or without aura; 24.3% vs 13.1%), & 12 of 16 key 2EPs, incl. freedom from MBS, also achieved significance; data to be presented at the European Headache Congress 2025
- Additionally, AbbVie has submitted an application to the EMA seeking expanded use for acute migraine treatment across EU
Ref: PRNewsWire| Image: AbbVie | Press Release
Related News:- AbbVie Reports Topline P-III (M19-044) Trial Data on Rinvoq (Upadacitinib) to Treat Non-Segmental Vitiligo
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
